Our results show that RAD51 foci in PDX tumor samples correlated with PARPi response, while BRCA1 promoter hypermethylation, BRCA1 expression, BRCA1 foci, or HRR gene mutations did not fully correlate with PARPi response. Here, RAD51 is linked to neoplasm.